High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation.

@article{Chang2007HighLO,
  title={High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation.},
  author={Ji Suk Chang and Ramasamy Santhanam and Rossana Trotta and Paolo Neviani and Anna M. Eiring and Edward L. Briercheck and Mattia Ronchetti and Denis Claude Roy and Bruno Calabretta and Michael A. Caligiuri and Danilo Perrotti},
  journal={Blood},
  year={2007},
  volume={110 3},
  pages={994-1003}
}
The inability of myeloid chronic myelogenous leukemia blast crisis (CML-BC) progenitors to undergo neutrophil differentiation depends on suppression of C/EBPalpha expression through the translation inhibitory activity of the RNA-binding protein hnRNP-E2. Here we show that "oncogene dosage" is a determinant factor for suppression of differentiation in CML-BC. In fact, high levels of p210-BCR/ABL are required for enhanced hnRNP-E2 expression, which depends on phosphorylation of hnRNP-E2 serines… CONTINUE READING